Alberta Investment Management Corp Bluebird Bio, Inc. Transaction History

Alberta Investment Management Corp

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 07, 2021	SELL	$16.59 - $33.89 $1.57 Million - $3.21 Million	-94,861 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$27.5 - $37.92 $382,965 - $528,073	-13,926 Reduced 12.8%	94,861 $4.11 Million
Q2 2020 Aug 11, 2020	BUY	$27.12 - $45.97 $470,667 - $797,809	17,355 Added 18.98%	108,787 $6.64 Million
Q1 2020 May 08, 2020	BUY	$26.16 - $63.5 $446,472 - $1.08 Million	17,067 Added 22.95%	91,432 $4.2 Million
Q4 2019 Feb 14, 2020	BUY	$46.96 - $61.67 $1.18 Million - $1.54 Million	25,027 Added 50.73%	74,365 $6.53 Million
Q3 2019 Oct 23, 2019	BUY	$59.47 - $93.1 $1.51 Million - $2.37 Million	25,405 Added 106.15%	49,338 $4.53 Million
Q2 2019 Aug 14, 2019	BUY	$75.84 - $105.21 $1.82 Million - $2.52 Million	23,933 New	23,933 $3.04 Million

151

64.4M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $27.8M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Alberta Investment Management Corp, based on Form 13F filings with the SEC.

Stay updated on Alberta Investment Management Corp with notifications on news.